Bioqual Inc BIOQ

$30.64 -2.36 (-7.15%)

Valuation

Market cap
27,405,000
Revenue TTM
$39,950,000
Net income TTM
$-4,170,000
PE ratio
0.00
Forward PE
—
Profit margin
-10.44%
Debt to equity
0.00

Trading

Volume
900
Avg volume
—
Day's range
$30.64 – $32.90
Shares out
894,000
Stochastic %K
0%
Beta
-0.10
Analysts
Strong Buy
Price target
—

Price

Company profile

Bioqual, Inc. provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States. The company provides contract research services in the areas of AIDS, influenza, respiratory syncytial virus, Coronavirus, malaria, hepatitis, cancer, and other infectious diseases, as well as flavivirus infections, including zika and dengue. It also offers small and large animal model...

Show more

Bioqual, Inc. provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States. The company provides contract research services in the areas of AIDS, influenza, respiratory syncytial virus, Coronavirus, malaria, hepatitis, cancer, and other infectious diseases, as well as flavivirus infections, including zika and dengue. It also offers small and large animal models. In addition, the company provides cell-based assays, immunoassay, toxicology and cytotoxicity testing, viral load testing, and tailored assay development services; and Biocontainment, imaging services, and animal model development; and IND-enabling services, such as toxicology studies, pharmacokinetic profiling, GLP services, and regulatory documentation services. Bioqual, Inc. was incorporated in 1981 and is based in Rockville, Maryland.

Industry
Diagnostics & Research
Sector
Healthcare
Phone
240 404 7654
Website
https://www.bioqual.com
Address
9620 Medical Center Drive, Suite 310, Rockville, United States

Latest news

No headlines yet.